KR20120119226A - Composition comprising the extract of seaweeds for prevention of losing hair or promotion of growing hair - Google Patents

Abstract

PURPOSE: A composition containing seaweed extract is provided to prevent hair loss, to promote hair growth, and to be applied in pharmaceutical and cosmetic fields. CONSTITUTION: A composition for preventing hair loss or promoting hair growth contains seaweed extract. The seaweed is 1-200 ug/ml of Ishige sinicola, 1-200 ug/ml of Grateloupia elliptica, or 1-100 ug/ml of Hizikia fusiformis (Harvey) Okamura. The composition is a pharmaceutical composition or a cosmetic composition. The pharmaceutical composition contains 10-20 parts by weight of the extract. The daily dose of the pharmaceutical composition is 0.1-500mg per 1kg of body weight. The pharmaceutical composition is manufactured in the form of powder, granules, tablet, capsule, suspension, emulsion, syrup, ointment, external use, suppository, or sterilized injection solution.

Description

Composition comprising the extract of seaweeds for prevention of losing hair or promotion of growing hair}

The present invention relates to a composition for preventing hair loss or promoting hair growth comprising an algae extract.

Human hair is about 100,000 to 150,000 pieces and is formed in "hair follicles". There is a papilla in the hair follicle, where the small blood vessels are distributed, providing the nutrients needed for hair growth and a seborrheic gland on the side of the teat that provides the oil to lubricate the hair.

Each hair has a different cycle and grows and falls through the anagen, catagen and telogen phases. This cycle is repeated over three to six years, with an average of 50 to 100 hairs falling out daily.

In general, alopecia refers to an abnormally high number of hairs falling out due to shortening of the growth phase hairs and more degenerative or resting hairs during these cycles.

The causes of hair loss are discussed, such as hyperthermia of male hormone action, excessive sebum secretion, poor blood circulation, hypoxia caused by peroxide, bacteria, genetic factors, aging, stress.

Specifically, testosteron, a type of male hormone, is activated as dihydrotestoserone (DHT) by an enzyme called 5α-reductase. Hair loss occurs by this DHT binding to specific receptors and inducing proteins that cause hair loss. In addition, by this mechanism, the sebum may be overproduced, and acne or seborrheic dermatitis may occur, causing hair loss with inflammation on the scalp.

However, in the case of preparations such as minoxidil or trichosaccharide, which are known to prevent hair loss and have an effect on promoting hair growth and hair growth, lack of obvious efficacy, human stability, and skin irritation are induced. Side effects such as these are emerging, it is urgent to develop a composition that ensures safety and efficacy.

Accordingly, the present inventors seek to provide a composition comprising a seaweed extract that is safe for skin and promotes hair loss prevention and hair growth in order to solve the problems as described above.

The present invention provides a composition for preventing hair loss or promoting hair growth comprising an extract of seaweed. In another aspect, the present invention provides a pharmaceutical composition and a cosmetic composition comprising the extract.

The composition comprising the seaweed extract according to the present invention is recognized to inhibit and prevent hair loss and promote hair growth, and can be used in various fields such as pharmacy, cosmetics and beauty.

Consistency of the present invention provides a composition for preventing hair loss or promoting hair growth comprising an extract of seaweed.

As used herein, the term “seaweed extract” refers to any one of the “broadspike extract”, “chamber extract”, and “” extract ”, and these are any one or more selected from the group consisting of the broadleaf, sesame gamble, and 톳. If it is obtained by extracting the active ingredient from the seaweed, it includes all without particular limitation. For example, the result obtained by adding broad strips, gambling gourds, or shells to water or an organic solvent and eluting the effective component through means such as standing, stirring, pressing, or heating may be mentioned. It also includes a freeze-dried product obtained by lyophilizing the liquid extract obtained as described above.

It also includes a powder obtained by pulverizing such a lyophilisate. In addition, any possible means for extracting the active ingredient includes all the extracted extracts, including all the processed after extraction and freeze-drying. Others include extracts obtained by conventional extraction methods such as extraction by baths or room temperature, or by conventional extraction methods described in Chinese medicine or textbooks.

In addition, it includes a fraction extract obtained through the Stass Otto extraction method, various column chromatography methods, etc., which is a special extraction method for separating specific active compounds.

The seaweed extract may be used without limitation, such as harvested, cultured or commercially available, and may include, for example, collecting and washing it with water to remove foreign substances and salts and then drying them.

The seaweed extract may be prepared by conventional extraction methods in the art, such as ultrasonic extraction, filtration and reflux extraction. Preferably any one or more selected from the group consisting of broad leaf, sesame gambling and 톳 may be an extract extracted with water, a lower alcohol of C1 ~ C4 or a mixed solvent thereof, more preferably a lower alcohol of C1 ~ C4 It may be an extract extracted, and most preferably may be an extract extracted with methanol or ethanol. For example, lyophilized rapeseed, sesame gamyeo or 톳 lyophilized and pulverized to a predetermined size and put in an extraction container, put a lower alcohol of C1 ~ C4 or a mixed solvent thereof, methanol or ethanol and extracted at room temperature, then left for a certain time The alcohol extract can be obtained by filtering with a filter paper. Extraction time may be 2 to 24 hours, 12 to 24 hours, 20 to 24 hours, and then may be additionally subjected to methods such as concentration or lyophilization.

The name is Ishige sinicola is an annual brown algae belonging to Phaeophyta, Phaeophyceae, Chordariales and Ishigeaceae. It is heterogeneous generation alternation, and frond is composed of milk tissues formed by attaching to other cell lines. The stellate is lobe and lobes are branched. The color of the frond is black yellow and the surface of the frond is a slippery substance. Roots are small platy, short circumferential stems, upper part broad broad or object, secondary branched. Sometimes it expands like a bubble because it has air in the tissue at the tip of the branch. Habitat inhabits temperate intertidal zones in the tropics. In Korea, it is known to be distributed throughout the southern coast and Jeju Island.

The Black Gambling ( Grateloupia) elliptica ) is a seaweed with red algae Jinuarit, 15-40 cm high, foliate, and diverged. It is a reddish purple, yellow, and green meat that turns purple when dried. Use it as a material for making grass or with glue. Gathers in rocky crevices on the coast and is distributed in Korea and Japan.

The algae are algae belonging to the brown algae, and contain a large amount of minerals such as iodine, potassium, calcium, iron, phosphorus, sodium, vitamin A, vitamin B1, vitamin B2 and the like. And 톳 extract helps the development of the human body, prevents aging, helps to form the skeleton and teeth of the human body as well as the effects of postpartum uterine contraction and hemostasis. In addition, iodine contained in the 톳 extract is absorbed in the body and then accumulated in the thyroid gland to form thyroid hormones to make the skin fine, elastic, and shiny.

As used herein, "hair loss" refers to a phenomenon in which hair falls off the scalp or a condition in which hair is coarse or thin, and "hair loss prevention" refers to preventing and suppressing hair loss as described above, and "hair growth". "Promoting" means not only promoting the production of new hair, but also keeping the existing hair healthy.

In general, "hair growth" occurs in the growth phase, and is promoted by induction from the resting phase to the growth phase and the delay from the growth phase to the regression phase. The hair cycle can be divided into three main stages, known as the growing, degenerative and resting phases. In the growth phase, hair growth occurs as hair follicles grow deep into the skin with rapid proliferation of cells. The next phenomenon is the degenerative phase, which is a transitional period in which the disruption of cell division is prominent, during which hair follicles gradually degenerate and hair growth stops. In the next phase, the resting phase, the degenerative hair follicles contain germs with densely packed dermal papilla cells. The onset of new growth phase phenomena at rest is induced by rapid cell proliferation in the embryo, swelling of the dermal papilla and the synthesis of basement membrane elements.

Therefore, it is necessary to prevent hair loss by promoting or extending the growth period, that is, to prevent hair loss or to cause regrowth of hair, that is, to promote hair growth, and the composition according to the embodiment of the present invention is to prevent hair from already existing. One or more of an effect of not falling out, an effect of thickening already existing hair, and the like, and an effect of generating new hair. In addition, the composition according to the present invention can activate hair papilla cells to induce hair growth.

In a specific embodiment of the present invention, 5α-reductase inhibitory effect and PGE2 production activity were evaluated in order to measure the hair loss prevention or hair growth promoting effect of any one or more seaweed extracts selected from the group consisting of broad leaf, sesame gambling, and 톳. Interleukin-12, Interleukin 6 and TNF-α production inhibitory activity was tested to determine inflammatory activity. In the case of 5α-reductase inhibitory effect, it showed excellent efficacy in the case of broad leaf and gambling gamyeo and superior to 톳 (Table 1). In addition, the hair growth efficacy was investigated by the amount of PGE ₂ produced by treating the algae extract in the HaCaT cell line, which is a keratinocyte, skin cells showed similar activity, and the broader than the 우수한 (Table 2). That is, the concentration of the broad leaf extract is 1 ~ 200 ug / mL, 10 ~ 200 ug / mL, the concentration of sesame gamyeo 1 ~ 200 ug / mL, 10 ~ 200 ug / mL, the concentration of 1 1 ~ 100 ug / mL, 10 ~ 100 ug / mL was found to be excellent in hair loss prevention or hair growth promoting effect.

The present invention also provides a pharmaceutical composition comprising a composition comprising a seaweed extract.

The seaweed extract may include 10 to 20 parts by weight based on 100 parts by weight of the total composition in the pharmaceutical composition.

The pharmaceutical composition of the present invention may be in various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.

As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The pharmaceutical dosage forms of the compositions of the present invention may also be used in the form of their pharmaceutically acceptable salts and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set. The salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzene sulfonic acid, toluene sulfonic acid, naphthalene sulfonic acid and the like can be used.

The composition of the present invention may be administered parenterally or orally as desired, and may be administered in one to several times to be administered in an amount of 0.1 to 500 mg, 1 to 100 mg per kg of body weight per day. The dosage for a particular patient may vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of the disease, and the like.

The pharmaceutical composition according to the present invention may be a powder, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations such as aerosols, external preparations such as ointments, creams, suppositories, and sterile injectable solutions, etc. according to conventional methods. It may be used in formulated in any form suitable for pharmaceutical formulations.

The composition according to the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes, such as parenteral, oral, and all modes of administration can be expected, for example, oral, rectal Or by intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

On the other hand, the composition according to the present invention, there is no serious toxicity and side effects can be used with confidence even for long-term use for the purpose of prevention.

The invention also provides a cosmetic composition comprising a composition comprising a seaweed extract.

The seaweed extract may be included in the pharmaceutical composition, 0.1 to 5% by weight.

The cosmetic composition may be a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier, Cosmetics or skin, such as fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in cosmetics It may contain adjuvants commonly used in the scientific field. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.

The cosmetic composition accordingly may for example be a cosmetic composition, the appearance of which comprises a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example, emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) obtained by dispersing the oil phase in solutions, gels, solids, pasty anhydrous products, aqueous phases, and It may be provided in the form of a nonionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. These compositions may be prepared according to conventional methods in the art. The composition according to the invention may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition comprising the seaweed extract is not particularly limited in the formulation, for example, supple cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam It can be formulated into cosmetics such as cleansing water, packs, powders, body lotions, body creams, body oils and body essences.

The cosmetic composition as described above may be applied in a form applied to the skin, or may be applied in a form that is absorbed into the skin using a microneedle or the like.

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention, but the scope of the present invention is not limited to the following examples. Embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.

Example 1 Collection and Extraction of Lobster , Charm Gambling, and Shellfish

The widespread, cham-gam gam and 톳 used for the test were taken directly from the coast of Jeju, washed with water several times, removed from foreign substances, and stored in a deep-freeze (-70 ℃).

Frozen samples were ground by lyophilization and powdered to a size of 50 mesh or less.

To 1 g of the dried powder, 100 ml of 70% ethanol was added and extracted at room temperature for 24 hours. Filtering was performed to remove residues that were not extracted in 70% ethanol. The extract was volatilized using a vacuum concentrator, dissolved in DMSO, and then stored at 4 ° C. to evaluate hair growth-related activity of the extract.

< Example  2> 5α- reductase  Inhibitory effect

5α-reductase activity was evaluated with the amount of rat prostate 5α-reductase by ^[3 H] testosterone (testosterone, T) is added by using this is converted to ^[3 H] dihydrotestosterone (dihydrotestosterone, DHT). SD males 7-8 weeks old were anesthetized with ethyl ether, slaughtered by cervical spine, and extracted from the prostate gland, immediately stored in liquid nitrogen. The required amount of prostate was taken out for each experiment. Prostate is placed in a glass homogenizer with homogenizer buffer (20 mM potassium phosphate (pH6.6), 0.32 M sucrose, 1 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonylfluoride (PMSF)) at 4 ° C and pulverized until cloudy. It was. After centrifugation (1500 g, 20 min, 4 ° C.), pellets were obtained, washed twice, and the homogenizer buffer was added to the pellets to suspension and used as a coenzyme. The 5α-reductase assay was performed as follows.

Microtube (microtube) and the crude enzyme sample and a reaction buffer (40 mM potassium phosphate (pH6.6) , 200 uM NADPH, 1 mM DTT, 120 nCi [1,2,6,7- 3 H] T) to put the The final reaction solution was adjusted to 500 µl and then reacted at 37 ° C for 60 minutes. 1 mL of ethyl acetate was added to vortex, centrifuged (1000 g, 5 min), the supernatant was taken, transferred to a new microtube, and dried completely using a heating plate (60 ° C.). 50 μl of ethyl acetate was added to the microtube, spotted on a TLC plate and developed three times under a developing solvent (50% cyclohexane, 50% ethyl acetate). T (testosterone) was identified at 254 nm by UV spectrometer and DHT (dihydrotestosterone) was confirmed by spraying 10% sulfuric acid. T and DHT sites were cut out with scissors and placed in each scintilation vial, followed by 10 mL of cocktail and measured by β-counter. The conversion of testosterone by 5α-reductase activity was calculated as the ratio of DHT / (T + DHT). Finasteride (Propecia ^?: Merck Sharp & Dohme (Australia) Pty. Ltd., Australia) having Type 2 5α-reductase inhibitory efficacy was used as a control.

Whether broad-leafed and gambling extracts can inhibit 5α-reductase activity, which is important in androgenetic alopecia, [ ³ H] testosterone (T) added using rat prostate 5α-reductase is converted to [ ³ H] dihydrotestosterone (DHT) The amount was evaluated (Table 1). Table 1 below evaluates important testosterone 5α-reductase inhibitory activity in androgenetic alopecia.

As a result, it was observed that the testosterone 5α-reductase activity was inhibited by 97.5 ± 7.5% ( P <0.05) by finasteride used as a positive control.

On the other hand, when treated with 0.1, 1 and 10 ug / mL concentrations, 16.3 ± 5.3% ( P <0.05), 39.8 ± 8.7% ( P <0.05) and 41.2 ± 2.0% ( P <0.05), respectively. Testosterone 5α-reductase inhibitory activity of 7.2 ± 6.1%, 14.7 ± 8.5% ( P <0.05) and 48.3 ± 8.9% ( P <0.05) when treated with 0.1, 1 and 10 ug / mL concentrations, respectively It was confirmed.

In the case of the already known hair growth efficiency in seaweeds, the concentrations of 8.0 ± 5.2%, 27.3 ± 4.4% ( P <0.05) and 33.3 ± 3.7% ( P <0.05) when treated at 0.1, 1 and 10 ug / mL concentrations, respectively testosterone 5α-reductase inhibitory activity was shown. As a result of the evaluation of testosterone 5α-reductase inhibitory activity, the hair growth activity of gambling and broad-loaf was better than that of 톳.

< Example  3> Wide , Gambling  And 톳 PGE ₂ Production activity evaluation

The hair growth efficacy of Jeju seaweed extract was investigated by the amount of PGE ₂ produced by treating seaweed extract on HaCaT cell line, a keratinocyte.

HaCaT cell 2.0x10 ⁵ cells / ml (96 well plate) seeding and 18h incubation (37 ℃, 5% CO ₂ ) and the samples were treated by concentration 24h after incubation. The supernatant in the culture was taken and PGE ₂ was quantified by ELISA.

233.9 pg / ml of PGE ₂ was produced from 100 μM of minoxidil sulfate used as a positive control, and the concentration-dependent PGE at 25, 100 μg / mL and gambling and broad-leaved 200, 50, 25 and 12.5 μg / mL ₂ The production effect was shown. Charm gamble was similar to that of ,, and broad-lead showed good activity compared to 톳 (Table 2). Table 2 below evaluates PGF2 production activity.

sample Concentration  (/ / ml ) PGE2  ( pg Of ml ) Minoxidil 100 μM 233.9 ± 41.1 톳 100 641.4 ± 37.83 25 139.6 ± 15.1 Gambling 200 982.6 ± 69.38 50 232.4 ± 26.9 25 81.3 ± 11.1 12.5 4.3 ± 14.8 Wide 200 1443.7 ± 81.04 50 698.8 ± 28.2 25 232.4 ± 26.9 12.5 0.0

< Example  4> interleukin-12, interleukin 6 and TNF -α production inhibitory activity evaluation

To evaluate the anti-inflammatory activity of the compounds, the inhibitory effect of the extract on the production of IL-12B (p40), interleukin 6 and TNF-α in LPS-stimulated myeloid-derived dendritic cells was tested. Bone marrow-derived dendritic cells were recovered from wild-type C57BL / 6 mice (Taconic Farm, Inc) and used. After bone marrow is recovered by spraying the tibia and femur from the mouse with DMEM (Invitrogen) medium, the bone marrow cells are cultured with 3% J558L lymphoma cell tumor supernatant containing GM-CSF. ) Was cultured in RPMI 1640 medium (10% heat-inactivated FBS, 50 μM 2-ME, and 2 mM glutamine). Medium was changed every other day with gastric culture medium containing GM-CSF.

Six days later, non-adherent cells and loosely adherent dendritic cells were recovered and suspended in RPMI 1640 (5% FBS). Dendritic cells (DCs) were dispensed in 48-well plates at 1 × 10 ⁵ cells / 0.5 mL, and then treated with the extract of the present invention at a concentration of 50 μg / mL 1 hour prior to Salmonella minnesota-derived LPS (Alexis, 10 ng / mL) was further treated. After 16 hours, the cell culture supernatant was recovered and the amount of IL-12B (p40), interleukin 6 and TNF-α in mouse interleukin-12 was measured by ELISA (BD PharMingen). All experiments were repeated three times and the data were expressed as mean ± standard deviation of the measurements obtained from three replicates. The data in the table expressed the degree of inhibition of production as a percentage (%) compared to the case treated with 0.1% DMSO (vehicle).

The broadleaf extract inhibited 96.5% of IL-12p40 production at a concentration of 50 μg / mL. At the same concentration, Charm gourd extract and musk showed inhibitory effects of 47.8 and 95.6%, respectively (Table 3).

The broadleaf extract inhibited 85.0% of IL-6 production at a concentration of 50 μg / mL. At the same concentration, Charm gourd extract and musk showed inhibitory effects of 31.4 and 73.2%, respectively (Table 3).

The broadleaf extract inhibited 47.2% of TNF-α production at a concentration of 50 μg / mL. At the same concentration, Charm gourd extract and 톳 showed inhibitory effects of 4.7 and 34.1%, respectively (Table 3). Table 3 below is an experimental result of measuring the inhibitory effect of the extract of the present invention on the production of interleukin 12 (IL-12), interleukin 6 (IL-6), and TNF-α in LPS-stimulated bone marrow-derived dendritic cells.

Extract persons Production Inhibition Effect (%) IL -12 p40 IL -6 TNF -α Wide 96.54 ± 0.0 85.03 ± 0.45 47.20 ± 1.29 Gambling 47.80 ± 5.95 31.49 ± 5.62 4.76 ± 5.69 톳 95.63 ± 1.58 73.23 ± 2.62 34.11 ± 3.11

Hereinafter, the preparation examples of the composition according to an embodiment of the present invention will be described, but the present invention is not intended to be limited thereto but merely to be described in detail.

Formulation example  1. Preparation of tablets

Each seaweed extract of Example 1. ... ... ... .100 mg

Corn Starch ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .68 mg

Lactose ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 90 mg

Microcrystalline cellulose… ... ... ... ... ... ... ... ... ... ... .40 mg

Magnesium stearate ... ... ... ... ... ... ... ... ... ... 2 mg

According to the conventional method of preparing tablets, the above ingredients were added to the indicated contents, mixed uniformly, stirred and granulated. After drying, using a tableting machine, a desired tablet containing 100 mg of each seaweed extract, which is one active ingredient, was prepared.

Formulation example  2. Preparation of capsule

Each seaweed extract of Example 1. ... ... ... ... ... ... ... 100 mg

Corn Starch ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 68 mg

Lactose ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 90 mg

Microcrystalline cellulose… ... ... ... ... ... ... ... ... ... ... ... ... 40 mg

Magnesium stearate ... ... ... ... ... ... ... ... ... ... ... 2 mg

According to the conventional method for preparing the capsules, the above-mentioned ingredients were added to the indicated contents, mixed uniformly, and then filled into gelatin capsules of appropriate size to contain 100 mg of each seaweed extract per capsule, thereby preparing the desired capsules.

Formulation example  3. Softening Cosmetics (Skin Lotion)

According to the composition described in Table 4 it was prepared in a flexible method in a conventional manner.

Formulation example  4. Pack

The pack was prepared by a conventional method according to the composition described in Table 5.

Claims (7)

A composition for preventing hair loss or promoting hair growth comprising an extract of seaweed. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein the seaweed is at least one member selected from the group consisting of broad leaf, black gambling, and shellfish. The composition for preventing hair loss or promoting hair growth according to claim 2, wherein the concentration of the broad leaf extract is 1 to 200 ug / mL. The composition for preventing hair loss or promoting hair growth according to claim 2, wherein the concentration of the true gambling extract is 1 to 200 ug / mL. The composition for preventing hair loss or promoting hair growth, characterized in that the concentration of the 톳 extract is 1 ~ 100 ug / mL. A pharmaceutical composition comprising a composition for preventing hair loss or promoting hair growth according to any one of claims 1 to 5. Cosmetic composition comprising a composition for preventing hair loss or promoting hair growth according to any one of claims 1 to 5.